Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. (PharmacoEconomics, 2011)

(untitled) - Dakin, H; Sherman, M; Fung, S; Fidler, C; Bentley, A